Frost & Sullivan: Setting the Stage for What's Next in Medical Devices

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 7
• Langue: English

Extrait

Frost & Sullivan: Setting the Stage for What's
Next in Medical Devices
PR Newswire
MOUNTAIN VIEW, California, Sept. 25, 2012

-- Companies attempt to adapt to the new reality of the evolving
healthcare landscape
MOUNTAIN VIEW, California
,
Sept. 25, 2012
/PRNewswire/ -- The medical device
industry continues to be one of the most vital and dynamic sectors of the U.S.
economy and a leading force in the revolution that is transforming the U.S.
healthcare system. However, the industry is undergoing a transition to adapt to
new business models that are changing the way care is delivered and paid for
in the United States.
New analysis from Frost & Sullivan's (http://www.medicaldevices.frost.com)
2012 United States Medical Devices Outlook
finds total market revenues
in 2011 were
$102.1 billion
, with a forecast of
$156.8 billion
projected in 2018.
The overall compound annual growth rate (CAGR) for the forecast period is a
modest 6.3 percent. While top-line growth is a virtual certainty, cost-
containment initiatives in the healthcare industry are forcing pricing pressure
with a medical device excise tax to go into effect in 2013 that could strain
margins for most companies.
For the full multimedia experience of this release, please send an email to Britni
Myers, Corporate Communications, at [e-mail], with your full
name, company name, job title, telephone number, company email address,
company website, city, state and country.
"In retrospect, the medical device market witnessed unprecedented growth
between 1995 and 2005. New technologies helped spur a revolution with
minimally invasive tools and implants that improved function and safety," said
Frost & Sullivan Advanced Medical Technologies Industry Manager Venkat
Rajan. "These novel developments allowed for new treatments and an
expansion of addressable conditions."
That growth, coupled with the potential impact of the baby boomer population,
led many in the industry to assume that the marketplace was recession-
resilient, if not recession-proof. However, the impact of the global economic
crisis in 2008 combined with healthcare reform measures aimed at cost
containment have significantly altered those expectations. In order to better
align with the realities of the current market, a number of companies have
undergone significant restructuring, such as major divestitures, staff cuts, and
turnover in senior management.
"In spite of the challenges, that is not to say that there are not significant
opportunities in the market that can be taken advantage of," said Rajan. "A
historic surge in demand resulting from an aging population with escalating
incidence rates for chronic disease is creating new needs and customer
requirements. Furthermore, significant research breakthroughs and leaps in
technology are drastically advancing the state of modern medicine."
Cutting edge companies are targeting products that fit in the vision of where
healthcare is heading, as opposed to where it is now. They have realized it is
not just about innovations to their products, but the business model as well.

not just about innovations to their products, but the business model as well.
Decisions are not made purely on clinical efficacy, but must also take into
account factors like ease of use, reimbursement, long term cost of care,
wellness, prevention and other advanced healthcare outcome measures.
The
2012 United States Medical Devices Outlook
is part of the
Advanced
Medical Technologies
Growth Partnership Services program, which also
includes research in the following markets:
Surgical Tools and Medical Implants
Medical Imaging Systems
Patient Monitoring and Diagnostic Tools
Chronic and Acute Disease Management Treatment Products

All research services included in subscriptions provide detailed market
opportunities and industry trends evaluated following extensive interviews with
market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with
clients to leverage visionary innovation that addresses the global challenges
and related growth opportunities that will make or break today's market
participants.
Our "Growth Partnership" supports clients by addressing these opportunities
and incorporating two key elements driving visionary innovation: The Integrated
Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition
provides support to our clients throughout all
phases of their journey to visionary innovation including: research, analysis, strategy,
vision, innovation and implementation.
The Partnership Infrastructure
is entirely unique as it constructs the foundation upon
which visionary innovation becomes possible. This includes our 360 degree research,
comprehensive industry coverage, career best practices as well as our global footprint
of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the
global 1000, emerging businesses, the public sector and the investment
community. Is your organization prepared for the next profound wave of
industry convergence, disruptive technologies, increasing competitive intensity,
Mega Trends, breakthrough best practices, changing customer dynamics and
emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
2012 United States Medical Devices Outlook
NB3E-54
Contact:
Britni Myers
Corporate Communications –
North America

P: [phone]
F: [phone]
E: [e-mail]
http://www.frost.com